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Abstract
Changes in morphology and growth curve of Candida albicans in response to treatment by Cisplatin
has been studied using fluorescence staining with ethidium bromide. Treatment with Cisplatin was
found to markedly inhibit hyphae and ovoid growth as revealed by ethidium bromide staining of
drug treated cells. These changes were concomitant with inhibitory effects on the growth curve
with respect to untreated cells
Presence of Cisplatin not only caused suppression in the limiting values in the growth curve, but
also caused a slight left shift in the EC50 values. Some of the ovoid cells undergoing poisoning with
cisplatin were found to be unusually enlarged before undergoing their natural fate thus suggesting
formation of similar cytotoxic end products with DNA.
Introduction
Candida albicans is a yeast pathogen that causes mild,
chronic, superficial systemic infections in immunocom-
promised and cancer patients [1-3]. Research, worldwide
is broadly focused on 1) search of new targets in C. alib-
cans, 2) Screening inhibitory activities with therapeutic
agents, and 3) designing or modifying novel agents, to
overcome treatment resistance [4]. C. alibcans has been
shown to harbor a self splicing group-I intron in the
nuclear 25s rRNA genes [5]. Presence of this gene in C.
alibcans, but not in the human genome, suggests that
splicing inhibitors could potentially act as alternate tar-
gets in controlling the proliferation of fungal pathogens.
Recent screening studies using disk diffusion have shown
that cis-diamminedichloro platinum (Cisplatin), a well-
established antitumor agent, inhibits the growth of C.
alibcans at lower concentrations [6]. Despite its prevalent
use in cancer treatment, very little work has been done [7-
10] to document the effects of Cisplatin and related metal
complexes in controlling the proliferation behavior of C.
alibcans. With the molecular mechanisms remaining
largely unknown, this provided us a basis to study the
effects of Cisplatin treatment on the morphology and
growth curve of C. alibcans. Morphological changes in
Candida can be followed by direct fluorescence staining
with suitable dyes to selectively visualize different parts/
aspects of cellular activities [11-13]. Though the use of
Ethidium Bromide for fluorescence staining is well
known, there is no report to show the use of this tech-
nique in studying the morphology of Candida, especially
in response to treatment with anticancer agents such as
Cisplatin. Herein, we report the morphological changes of
C. alibcans in response to cisplatin using fluorescence
microscopy with ethidium bromide staining.
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Materials and methods
Media and Inoculums
Yeast isolates (clinical strains) were obtained from
patients, Royapettah Hospital, Chennai. Sub-cultured iso-
lates were maintained in Sabouraud dextrose agar (B.B.L,
Cockeysville, MD) at 1–5 × 106 CFU/10 ml media. 30 µl
of each sample (log phase) was used for slide preparation
to study the morphological changes.
Drug preparation
A 2 mg/ml stock of Cisplatin (TNDPL, Chennai) was pre-
pared in sterile Millipore water. Stock was diluted to 60
µg/10 ml culture for treatment purposes.
Staining
Ethidium bromide staining was performed using a freshly
prepared stock of ethidium bromide (1 mg/ml water)
from which 50 µl/100 ml concentration was used for
staining the slides. Gram staining was performed from
commercially available kits as per instructions.
Morphological studies using Fluorescence Microscopy
30 µl of cultured C. alibcans (Drug treated/non-treated
cells) was taken and spread over the clean glass slide and
dried at 37°C for 5 minutes. Slides were dipped into the
EtBr staining solution for 30–40 seconds followed by
immersion in water for 15–20 seconds to remove excess
stain. Gram staining was performed in parallel on a simi-
lar set of slides to validate the results. Both the set of slides
were viewed using NFM under the 100× magnification.
Results and Discussion
Treatment of C. alibcans with Cisplatin was found to
markedly inhibit hyphae and ovoid growth (Fig. 2) as
revealed by ethidium bromide staining of drug treated
cells. This was in contrast to the controls showing mark-
edly branched hyphae, with budding characteristics (Fig.
Photograph showing morphology of Candida albicans in the absence of cisplatin (6 ug/ml), stained with ethidium bromide and  gram stain Figure 1
Photograph showing morphology of Candida albicans in the absence of cisplatin (6 ug/ml), stained with ethidium bromide and 
gram stain.
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1). The ovoid cells of Cisplatin treated C. alibcans showed
an increased uptake of the ethidium bromide stain (red
color) in contrast to the untreated counterparts (yellowish
orange), thus pointing to drug induced poisoning and
death of treated cells. These changes were concomitant
with inhibitory effects on the growth curve with respect to
untreated cells (Fig. 3). Presence of Cisplatin not only
caused suppression in the limiting growth values but
caused a slight left shift in the EC50 values, which remains
to be studied further. Some of the ovoid cells undergoing
poisoning with cisplatin were found to be unusually
enlarged before undergoing their natural fate (Fig. 2). This
is known to be one of the typical effects of poisoning with
cisplatin in case of tumor cell lines as well thus suggesting
formation of similar cytotoxic end products [14]. Cispla-
tin in water forms a diaqua species of Pt+2 due to the fast
leaving Cl- ions. This could lead further to host of reac-
tions in the cytoplasm before forming end products with
DNA. It is also possible that cisplatin exerts its activity
through other secondary response mechanisms. Further
studies using RT-PCR will elucidate 1) the role of the
Photograph showing morphology of Candida albicans in the presence or absence of cisplatin (6 ug/ml), stained with ethidium  bromide and gram stain Figure 2
Photograph showing morphology of Candida albicans in the presence or absence of cisplatin (6 ug/ml), stained with ethidium 
bromide and gram stain.
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Growth curve of Candida albicans in the presence/absence of  Cisplatin (6 µg/ml) Figure 3
Growth curve of Candida albicans in the presence/absence of 
Cisplatin (6 µg/ml). Curve fitting of data points was per-
formed using non-linear regression(sigmoidal curve): Graph-
Pad Prism Version 3.02.
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binding affinity of cis-DDP to certain RNA species in cyto-
toxicity against C. albicans, for example, group-I intron
ribozyme, known in many human diseases causing path-
ogens and a potential target site for therapeutic agents. 2)
Whether cis-DDP inhibits the C. alibcans growth through
penetration into the cell or some secondary response.
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